The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more
Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
Eli Lilly has signed back-to-back collaborations with SanegeneBio and MeiraGTx, advancing its genetic medicine portfolio across RNA interference and ophthalmic gene therapy. Together, the agreements deepen Lilly’s position in next-generation RNA- and DNA-based therapeutics.
Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s … Read more
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Metsera’s board has deemed Novo Nordisk’s $10 billion bid superior to Pfizer’s, setting off a high-stakes bidding and legal battle amid the obesity-drug gold rush.
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
Thermo Fisher acquisition hits billion mark for Clario.
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
Biogen strengthens Immunology pipeline through $1B Vanqua acquisition deal.